ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
The Serum Tissue Factor Level in Lung Cancer Patients as a Prognostic Factor

This study is currently recruiting participants.
Verified by National Taiwan University Hospital, June 2005

Sponsored by: National Taiwan University Hospital
Information provided by: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT00257179
  Purpose

This study uses serum tissue factor and tissue factor inhibitor and factor VII to monitor the pre-coagulation status in lung cancer patients and to correlate the pre-coagulation status with clinical staging and prognosis.


Condition
Lung Cancer

MedlinePlus related topics:   Cancer    Lung Cancer   

ChemIDplus related topics:   Thromboplastin   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Natural History, Cross-Sectional, Random Sample, Prospective Study

Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment:   200
Study Start Date:   June 2005

Detailed Description:

The staging of lung cancer was according to tumor size, involvement of lymph node and metastatic status. But there is a different prognosis in cancer patients of the same stage. The coagulation status of cancer patients was considered as an important possible prognostic factor. So in this study, we want to evaluate patients' coagulation status and find the relation of coagulation status and cancer status.

We thus propose a prospective study using coagulation factors in order to search for the relationship between cancer stage and pre-coagulation status in Taiwanese lung cancer patients. We will also evaluate the potential use of tissue factor as a prognosis predictor in lung cancer patients.

  Eligibility
Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Patients with newly-diagnosed lung cancer
  • Serum from cancer-free healthy volunteers

Exclusion Criteria:

  • Chronic renal failure or end-stage renal disease [ESRD] (creatinine [Cr] > 2 )
  • Hyperlipidemia on statin therapy
  • Acute myocardial infarction
  • Tapal or Plavix use
  • Active thromboembolic event
  • Severe liver disease (> child B)
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00257179

Contacts
Contact: Chong-Jen Yu, M.D., Ph.D.     886-2-2356-2905     jeffery@ha.mc.ntuh.edu.tw    

Locations
Taiwan
National Taiwan University Hospital     Recruiting
      Taipei, Taiwan
      Contact: Chong-Jen Yu, M.D., Ph.D.     886-2-2356-2905        

Sponsors and Collaborators
National Taiwan University Hospital

Investigators
Principal Investigator:     Chong-Jen Yu, M.D., Ph.D.     National Taiwan University Hospital    
  More Information


Study ID Numbers:   9461700609
First Received:   November 21, 2005
Last Updated:   March 13, 2006
ClinicalTrials.gov Identifier:   NCT00257179
Health Authority:   Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
Tissue factor  
Lung cancer  
Tissue factor protein inhibitor  
Factor VII  
Factor X  

Study placed in the following topic categories:
Thoracic Neoplasms
Respiratory Tract Diseases
Lung Neoplasms
Thromboplastin
Lung Diseases

Additional relevant MeSH terms:
Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Coagulants
Therapeutic Uses
Hematologic Agents
Pharmacologic Actions
Hemostatics

ClinicalTrials.gov processed this record on September 19, 2008




Links to all studies - primarily for crawlers